Ensoma IPO

www.ensoma.comHealthcare / BioTech & Pharma

Ensoma, founded in 2019, is a biotechnology company with the goal of expanding the reach of the curative power of genomic medicine by seeking to pioneer a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies aim to be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma is headquartered in Boston, Massachusetts.

Buy or sell Ensoma stock Learn more about Ensoma stock

Learn more about Ensoma

Is Ensoma a publicly traded company?

Ensoma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Ensoma go IPO?

Ensoma has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Ensoma's IPO price?

The IPO price for Ensoma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Ensoma pre-IPO?

Ensoma is privately held company and is not publicly traded, therefor investing in Ensoma pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Ensoma shares?

To determine the value of your Ensoma shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Ensoma shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Ensoma before it goes public?

Yes, you can seek to sell shares in Ensoma while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Ensoma's funding to date?

Ensoma has raised $163.05MM to date.

When was Ensoma founded?

Ensoma was founded in 2019.

Who are Ensoma's major investors?

Viking Global Investors

Takeda Ventures

Bill & Melinda Gates Foundation

RIT Capital Partners

F-Prime Capital

Qatar Investment Authority

Mirae Asset Global Investments

Cormorant Asset Management

Delos Capital

Catalio Capital Management

SymBiosis Capital Management

Arix Bioscience

Bioluminescence Ventures

Gilead Sciences

Solasta Ventures

5AM Ventures

Alexandria Venture Investments

Fred Hutchinson Cancer Research Center

Kite Pharma

Ensoma funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
4/13/2023	Series B	$92.5MM raised	$XXX.XX	$XXX.XX
2/11/2021	Series A and A-1	$70.55MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.